Study to evaluate the effect of rovalpituzumab tesirine on cardiac ventricular repolarization
in subjects with small cell lung cancer (SCLC).
Drug: Rovalpituzumab Tesirine
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02874664
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Histologically or cytologically confirmed extensive-stage small-cell lung cancer
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Adequate hematologic and organ function as confirmed by laboratory values
Clinically significant cardiac abnormalities including QRS duration of >120 msec; QTcF
>470 msec for women and >450 msec for men; Abnormal cardiac rhythm; Clinically significant cardiac valve abnormality; Documented history of left ventricular ejection fraction <0.30 within 6 months; Permanent pacemaker or automatic implantable cardioverter defibrillator; History of torsades de pointes, congenital long QT syndrome, or family history of long QT syndrome or sudden death
Recent or ongoing serious infection
Women who are pregnant or breastfeeding
Prior exposure to a pyrrolobenzodiazepine (PBD)-based drug, prior participation in a rovalpituzumab tesirine clinical trial, or known hypersensitivity to rovalpituzumab tesirine or excipient contained in the drug formulation.
All locations for NCT02874664
United States (13)
University of California Los Angeles
Los Angeles, California, United States, 90404
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States, 30322
University of Chicago
Chicago, Illinois, United States, 60637
Parkview Research Center
Fort Wayne, Indiana, United States, 46845
Baptist Health Lexington
Lexington, Kentucky, United States, 40503
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
University of Cincinnati
Cincinnati, Ohio, United States, 45267
University Hospitals Case Medical Center
Cleveland, Ohio, United States, 44106
Cleveland, Ohio, United States, 44109
Greenville Health System
Greenville, South Carolina, United States, 29605
Mary Crowley Medical Research Center
Dallas, Texas, United States, 75230
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
The Ottawa Hospital-Cancer Centre
Ottawa, Ontario, Canada, K1H 8L6
View full eligibility
Tris trial is registered with FDA with number: NCT02874664. The sponsor of the trial is Stemcentrx and it is looking for 46 volunteers for the current phase.
Official trial title: An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.